ZIOPHARM Oncology, Inc. - Special Call Transcript
Good morning, and welcome to the Ziopharm Oncology 2021 R&D Day. My name is Adam Levy, and I'm EVP of Investor Relations and Corporate Communications.
I'd like to begin by reviewing some disclosures pertaining to the session today. First, during this event, speakers may make forward-looking statements regarding the potential therapeutic candidates in our development pipeline, regulatory status, financial information and business trends. Forward-looking statements are subject to numerous risks and uncertainties, as described in our 10-K and within other filings that we may make with the SEC from time to time.
Also please note that the event features presentations from external speakers, and those views are not being provided by the company and may not reflect the views of Ziopharm or its management team. You should also be aware that not all speakers have agreed to distribute their materials on our website or in the downloadable materials on this webcast.
Turning now to the purpose of today's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |